A Phase 4 interventional study of Semaglutide and Virtual Weight Management Coaching in Obesity and Chronic Kidney Disease, sponsored by Western University, Canada. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by Western University, Canada · Phase 4, Interventional, and Other
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 145 studies testing semaglutide in Obesity — 70 open to participants now, 79 under way, 15 of them phase 3. Semaglutide · Obesity.
Among the 145 studies testing semaglutide in Obesity, this one is the 101st largest by planned enrollment, is one of 19 that started in 2024, is one of 40 in phase 4, reaches primary completion later than 15 of the 78 other live ones, and was the 75th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →70 of the 145 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
McMaster University · Sites in Canada
Ages 18–60
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
145 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 25 · Phase 3 47 · Phase 4 40
First in 2014; this study’s year is marked. 19 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 100 across the 145 interventional studies. Of the 60 that completed or were terminated, 35 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 145 have an industry lead sponsor. The 10 most frequent:
Western University, Canada is the lead sponsor of 224 studies on the registry; 56 are open to participants now.
Western University, Canada has 6 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
22 of the studies testing semaglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07740291Texas Tech UniversityTirzepatide Impact Assessment Study | 2026-11-23 |
| NCT07430059Vivani Medical, IncSafety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | 2026-12 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
| NCT05173714Srinvasan BeddhuSit Less, Interact and Move More (SLIMM) 2 Study | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 145 studies testing semaglutide in Obesity, from their registry updates:
This tab as a report to print or save as PDF → With an account.
OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial.
We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.
Obesity is well-recognized as an independent risk factor for chronic kidney disease (CKD) including end-staged kidney disease (ESKD). In people with ESKD, obesity can preclude access to lifesaving kidney transplantation. Of solid organ transplant programs in Canada, 80% exclude people with obesity (based upon body mass index or BMI), due to a potential risk of perioperative complications and post-transplant mortality.
Losing weight for kidney transplantation can, however, be extremely difficult. Medications that can promote weight loss in other populations including glucagon-like peptide 1 receptor agonists (GLP-1RA; liraglutide, semaglutide, and dulaglutide) and glucose-dependent insulinotropic polypeptide (GIP-1RA)/GLP-1RAs (tirzepatide), have not been studied in devoted trials of advanced CKD participants, and their efficacy and safety remain unclear.
Nutritional advice is often very difficult to follow when trying to balance kidney and diabetes diets (e.g. potassium), and if diets are too restrictive, there may be protein-energy wasting which could be detrimental to patients. People with high-risk CKD frequently live with functional impairment which can limit exercise. Weight loss programs can be cost prohibitive to those who are already socioeconomically disadvantaged.
A vanguard is needed before a large, multicentered RCT: A feasibility study will allow us to ensure that we can recruit a sufficient sample of participants into our trial, that our trial processes are inclusive, and that they are acceptable to patients. In the vanguard phase of our trial, we will answer the following questions:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A maximum tolerated dose of semaglutide (Ozempic/Wegovy) will be administered once weekly subcutaneously, up to a dose of 2.0 mg. Participants will also receive nutritional and movement advice, as well as virtual coaching once every 4 weeks for 6 months.
Drug: Semaglutide · Behavioral: Virtual Weight Management Coaching
Usual care participants will continue to receive the typical standard of kidney and diabetes care. They will not receive any study medication or coaching.
Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.
Also known as: GLP-1RA, Ozempic, Wegovy
Virtual meeting with intervention coach once every 4 weeks for 6 months, where the coach will discuss the goals and progress with participant, nutritional advice, exercise advice, and motivational support.
Feasibility of Recruitment
Number of participants enrolled across three centers, with success defined as recruitment of ≥ 60 participants within the 12-month enrollment period.
Time frame: 12 months
Adherence to Scheduled Coaching Visits
Percentage of participants randomized to the intervention attend \>75% of their scheduled coaching visits.
Time frame: 12 months
Adherence to GLP-1RA Therapy
Percentage of participants randomized to the intervention fill \>75% of their semaglutide prescriptions.
Time frame: 12 months
Recruitment of ≥20 Participants in First 12 Weeks
Recruitment of ≥20 participants in first 12 Weeks of trial initiation
Time frame: First 12 weeks
Recruitment Per Site Within 12 Weeks
At least one participant recruited per site within 12 weeks of trial initiation each active site
Time frame: First 12 weeks
Incidence of Acute Kidney Injury
Number of participants experiencing acute kidney injury (AKI)
Time frame: 12 months
Incidence of Hypoglycemia
Number of participants experiencing hypoglycemia
Time frame: 12 months
Incidence of Gastrointestinal Side Effects
Number of participants experiencing GI side effects
Time frame: 12 months
Change in Dalhousie Clinical Frailty Scale Classification
Change in participant's Dalhousie Clinical Frailty Scale Classification from baseline to 26 weeks. The scale has 9 options, from 1 (very fit) to 9 (terminally ill).
Time frame: 26 weeks
Change in SARC-F Score of Sarcopenia
Change in participant's SARC-F questionnaire score from baseline to 26 weeks. Out of 8 points, a SARC-F score of ≥4 best predicts the need for further, more comprehensive clinical evaluation.
Time frame: 26 weeks
Change in Body Weight - Smart Scale
Change in weight from baseline to 26 weeks, measured in kilograms. Measured using a Smart Scale in a subpopulation.
Time frame: 26 weeks
Change in Body Fat - Smart Scale
Change in body fat from baseline to 26 weeks, measured in percentage. Measured using Smart Scale in subpopulation.
Time frame: 26 weeks
Change in Muscle Mass - Smart Scale
Change in muscle mass from baseline to 26 weeks. Measured in kilograms. Measured using Smart Scale in subpopulation.
Time frame: 26 weeks
Change in Body Water Content - Smart Scale
Change in body water content from baseline to 26 weeks. Measured in percentage. Measured using Smart Scale in subpopulation.
Time frame: 26 weeks
In-Clinic Height Measurement
In-clinic height measurements, measured in centimeters
Time frame: Baseline, 3 months, 6 months
In-Clinic Weight Measurement
In-clinic weight measurements, measured in kilograms
Time frame: Baseline, 3 months, 6 months
In-Clinic Body Mass Index Measurement
In-clinic BMI measurements, measured in kg/m\^2
Time frame: Baseline, 3 months, 6 months
Percentage of Change in HbA1c
Percentage of change in HbA1c from baseline to 26 weeks, measured in percentage
Time frame: 26 weeks
Change in 2-week glycemic variability
For those using a Libre or Continuous Glucose Monitoring at baseline, Percentage of change in 2-week glycemic variability from baseline to 26 weeks
Time frame: 26 weeks
Change in Time-in-Range
For those using a Libre or Continuous Glucose Monitoring at baseline, Percentage of change in Time-in-Range from baseline to 26 weeks
Time frame: 26 weeks
Plan to share: Yes — Demographics (age, sex, etc.) Baseline characteristics Lab Values Outcome Measurements Adverse event data Other data points collected for each participant
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning immediately following publication; no end date
Access criteria: De-identified individual participant data will be made available to qualified researchers who provide a methodologically sound research proposal. Requests will be reviewed by the study investigators. Data will be provided following execution of an appropriate data use agreement.
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Sep 2026, 24 months after the start.
Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 24 months is below that.
Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide